However, no significant increase was recorded in BCRP level for BMA-treated CASD1 knockout cancer cells suggesting that lysosomal degradation pathway may also be responsible for modulating levels of acetyl modified glycoproteins including BCRP. The gene discussed is CASD1; the disease is cancer.